13 OCT

Radisson Blu Hotel Zurich Airport

CHECK OUT OUR **STRATEGY DINNERS**
On Pages 6 and 7
LIMITED SPACE ONLY **BOOK NOW**

Proventa International's 4th Annual

MEDICINAL CHEMISTRY STRATEGY MEETING EUROPE 2022

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

- Drug Discovery
- AI/ML
- Chemical Biology
- Integrated Drug Discovery
- New Modalities
- Automation
- Hit ID
- Lead Optimization
- High-Throughput Screening
- Cheminformatics
- Targeted Protein Degradation

Featuring Industry Leaders and Decision Makers

Guido Koch
Chief Executive Officer
Amphilix

Asif Ahmed
Executive Chairman and CEO
Mirzyme

Philippe Pinton
Vice President and Global Head Translational Medicine & Clinical Pharmacology
Ferring Pharmaceutical

Daniel Gironés
Senior Vice President Drug Discovery
Protinhi Therapeutics

Edgar Jacoby
Senior Principal Scientist Computational Chemistry
The Janssen Pharmaceutical Companies of Johnson & Johnson

Stefan Schiesser
Associate Principal Scientist
AstraZeneca

Henrik Keränen
Research Scientist and Head of Computational Chemistry Section,
Lundbeck

OUR SPONSORS

Ainnocence · Enamine · optibrium · Piramal Pharma Solutions · AF ChemPharm · aragen · Medicilon · PerkinElmer For the Better · PELAGO BIOSCIENCE · CDD VAULT Complexity Simplified

Click here to find out what our clients think about our **STRATEGY MEETINGS!**

Register Now! →

proventainternational.com
UK: +44 (0)20 3314 0100 | **US:** +1 (617) 614 0377
info@proventainternational.com
Proventa International
@proventaintl
@proventainternational
PROVENTA INTERNATIONAL

Proventa International's Strategy Meetings are a completely unique experience.

MEDICINAL CHEMISTRY
STRATEGY MEETING
EUROPE 2022

13 OCT

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

With the growing excitement brought by advances in protein structure prediction, using RNA and small molecules as therapeutic, and drugging the undruggable, we have come a long way despite the implications of the pandemic on industry output. Despite the increased innovation, quality of methods, and techniques geared toward the discovery and optimization, maintaining productivity, a consistent rollout of successful drug candidates, along with unlocking the most favorable targets remain an industry challenge.

At **PROVENTA'S 4TH ANNUAL MEDICINAL CHEMISTRY STRATEGY MEETING** in Zurich, senior leaders in Medicinal Chemistry will gather for candid and strategic discussions to ensure the most impactful challenges are being addressed and solutions uncovered.

This meeting aims to push the boundaries of the medicinal chemist's toolkit through

- ☑ Discussions on the advancements in targeted protein degradation and pushing past its boundaries
- ☑ Understanding contemporary developments and alternatives for drug discovery, development, and preclinical phases
- ☑ Leveraging Artificial Intelligence and Machine Learning in accelerating the development of new drugs
- ☑ Investigating AI's effective and practical uses in Structural Chemistry, ADMET predictions, Lead optimization, Small molecule drugs, and other areas
- ☑ The significance of innovative structural approaches such as NMR and Chemical probe in the early-phase of Drug Discovery
- ☑ Discuss approaches to further understand the interactions of undruggable targets and different Protein Degraders such as PROTACs, Molecular Glues, etc
- ☑ Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more

Join leading pharmaceutical and biotech experts to explore ideas and determine benchmark best practices to expand current knowledge and foster new and existing collaborations.

SENIORITY OF ATTENDEES



Facilitator Faculty

Dr. Lurong Pan
Founder and CEO
Ainnocence

Asif Ahmed
Executive Chairman and CEO
Mirzyme

Daniel Gironés
Senior Vice President Drug Discovery
Protinhi Therapeutics

Edgar Jacoby
Senior Principal Scientist Computational Chemistry
The Janssen Pharmaceutical Companies of Johnson & Johnson

Henrik Keränen
Research Scientist and Head of Computational Chemistry Section
Lundbeck

Guido Koch
Chief Executive Officer
Amphilix

Philippe Pinton
Vice President and Global Head Translational Medicine & Clinical Pharmacology
Ferring Pharmaceutical

Stefan Schiesser
Associate Principal Scientist
AstraZeneca

HOW HAS OUR Strategy Meetings Benefit The Life Science Industry

> *It was a great meeting. I enjoyed the round tables and seeing some old colleagues and meeting some new ones and continuing my string of attending every single one of your events from the first one!"*
>
> **Mark Tebbe** — *Co-Founder & CSO*, **Quench Bio**

> *It was a pleasure for me to participate. I love this series. Please keep it up!"*
>
> **Zhihua Sui** — *CSO, Head of Research & Preclinical Development*, **Proteovant Therapeutics**

> *The meeting was excellent. Discussions were great and trying to get everyone around the table to participate made for great idea sharing. I look forward to future meetings."*
>
> **Joseph Mancini** — *Head of Pharmacology*, **AdMare Bioinnovations**

Our Sponsors

Co-host Sponsors

Ainnocence created a fast and self-evolving artificial intelligence platform to simplify drug discovery and development. Ainnocence's platform integrates multiple advanced computational and wet lab technologies to accelerate the discovery and development process for both small molecule and protein therapies. Ainnocence software suite screens billions of chemical compounds, integrates binding prediction, off-target toxicity, and humanization into a single workflow, and simplifies and de-risks multiple steps in the discovery and development process. Ainnocence's advanced deep learning engine is constantly validated by industrial experts, and undergoes reinforcement learning cycles and automatic ETL processes. The platform currently offers small molecule, biologics and other new modalities' design services and pipeline collaborations.

VISIT WEBSITE

Enamine is a global leading designer and largest producer of building blocks (240,000+) and screening libraries (2.7M+ compounds). REAL® Database https://enamine.net/compound-collections/real-compounds/real-database is a collection of 4.1 billion enumerated compounds that can be synthesized within just 3 weeks with over 80% success rate. REAL® Space https:// enamine.net/compound-collections/real-compounds/real-space-navigator is a database of synthons and reactions that have been prepared to enable searches in around 20 billion possible combinations using infiniSee by BioSolveIT. MADE® Building Blocks https://enamine.net/building-blocks/make-on-demand-building-blocks are a catalogued collection of 210 million highly feasible building blocks. Enamine provides expertise in advanced organic synthesis, library synthesis, and medicinal chemistry. In 2011 Enamine established a pre-clinical service unit including ADME, in-vivo PK studies and High Throughput Screening under the brand name "Bienta", allowing the company to tackle since that time fully integrated or à-la-carte research program.

VISIT WEBSITE

Optibrium develops elegant software for small molecule design, optimisation and data analysis. StarDrop™ is Optibrium's best-in-class integrated modular software with a highly visual and user-friendly interface, enabling a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research. Cerella™, Optibrium's proven AI software, guides drug discovery, generating valuable and transformative insights from your compound data.

VISIT WEBSITE

Piramal Pharma Solutions (PPS) is a Contract Research Development and Manufacturing Organization (CDMO) offering end-to-end discovery, development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. The Discovery Services site of PPS has been operational since 2003 in Ahmedabad, India and currently have ~300+ chemistry FTE's and ~25 Biologists supporting various small molecule discovery programs in Hit to Lead and Lead Optimization stages and work on both FTE and Fee Based Models. Our capabilities include:

- Custom Synthesis of individual compounds, building blocks, scaffolds, focused libraries (40-100 compounds), reference standards, intermediates, impurities & metabolites
- DMPK
- Route Scouting leveraging our global process chemistry expertise across US, Canada & India to support early drug development
- Analytical services including method development (non-GMP), separation of Chiral/ Achiral compounds (mg-gm scale)

PPS also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product from 14 sites in India, UK, Canada and USA. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide. PPS is a subsidiary of the India based Healthcare and Financial Conglomerate -Piramal Enterprises Ltd (Market Cap - $5 Billion) and the Carlyle Group has recently acquired a 20% stake in PPS. For more information please visit: www.piramalpharmasolutions.com

VISIT WEBSITE

AF ChemPharm Services
A UK based CRO with PhD qualified scientists provides synthetic chemistry services supporting drug discovery in biotech/pharma around the world. We specialise in:

- Custom synthesis — We deliver a highly focused service for synthesis of small molecule targets, analogues from milligram to kilogram
- Computer aided drug discovery (CADD) — Established CADD tools allow us to provide discovery of targeted high-quality novel small molecules rapidly.
- Contract research and development and specialist consultancy — Operating from our state-of-the-art facilities, we work to optimise processes and refining operations.
- Research and collaboration — Our expertise has created bioactive molecules, novel compounds and screening libraries.

VISIT WEBSITE

Aragen Life Sciences (formerly, GVK BIO), is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. It offers end-to-end integrated or standalone solutions for small and large molecules. Established in 2001, the Company operates through a network of sites located globally with a team of 3000+ scientists and 450+ PhDs. Its expertise and experience have enabled over 450 customers in advancing their research programs from discovery through commercialization. Aragen's innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma, biotech, agrochemical, animal health and performance chemical industries globally. Visit www.aragen.com for more details.

VISIT WEBSITE

Medicilon is one of leading contract research organizations (CRO) with around 3,000 scientists and employees to serve over 1000 drug discovery companies and research projects for global clients from small novel drug research companies to the multinational pharmaceutical companies, such as Roche, GSK etc. Our 4 laboratories sites in Shanghai and Hangzhou are over 700,000 sq. ft. capacity to offer the fully integrated novel drug research services to help clients developing their research programs from the initial idea stage to the IND filing. The chemistry production facilities are GMP certified to compliance with main international regulatory bodies. The preclinical study laboratory is accredited AAALAC-certified animal research facility in compliance with US FDA GLP and China NMPA GLP standard.

VISIT WEBSITE

PerkinElmer Informatics offers one of the most comprehensive suites of scientific software in the world. Our powerful informatics solutions are used across a spectrum of industries including Pharma and Biotech, Specialty & Agro-Chemicals, Energy & Petrochemicals, Flavors & Fragrances, Food & Beverage and Electronics. Our future-proof technology enables investigators in Life Sciences to capture and analyze their data from initial research and development of their therapeutics, through biomarker discovery & patient stratifications and ultimately live tracking of their clinical trials. From our internationally recognized flagship ChemDraw® and E-Notebook applications, to our Signals Research Suite (Signals Notebook, Signals VitroVivo and Signals Inventa) to our exclusive TIBCO® Spotfire® partnership that brings scientific data analytics to visual life, no scientific company offers a wider range and more powerful suite of scientific solutions than PerkinElmer Informatics.

VISIT WEBSITE

Pelago Bioscience is a Discovery Research Partner focusing on biologically relevant systems, unleashing drug discovery projects using the patented CETSA® technology as a core pillar. The Cellular Thermal Shift Assay (CETSA® by Pelago Bioscience) has multiple assay formats that make it a keystone of decision making throughout the drug discovery pipeline. Unlike other solutions on the market today, its unique approach allows the assessment and quantification of target engagement under physiological conditions – without the need to modify the compound or protein. This provides data that is both actionable and biologically relevant. Think of CETSA® as snapshots of true target engagement inside the cell, any time you need them. Using CETSA® data and applications, our customers are able to make better and more informed decisions at earlier stages in their projects.

VISIT WEBSITE

Exhibitor

CDD VAULT Complexity Simplified

VISIT WEBSITE

How it Works?

Real insights are shared in conversations, not lectures. That's why our unique **roundtable** format guarantees real learning and ensures you only attend discussions that deliver value to you.

Join as many as four roundtable discussions, each with up to 20 other subject experts, networking with top-level peers in an informal, relaxed and sociable environment.

Simply follow the steps below to select your roundtable discussions and we'll create your own personalised agenda for the day:

01 EXPLORE THE FULL AGENDA

Select which roundtable discussions you would like to join. Our sessions are divided among 4 themed tracks for easy selection - you can choose to join any session you like.

02 COMPLETE YOUR SCHEDULING FORM

Select your preferred roundtable discussion for each time slot. We will send this form out via email a few weeks before the event - be sure to get your first choice by completing the form quickly.

03 ENJOY YOUR PERSONALISED EXPERIENCE

Join your selected roundtable sessions on the day. We will give you your personalised agenda containing the time and room assignments of your chosen roundtable discussions so you won't miss it.

Agenda at a Glance

Medicinal Chemistry Strategy Overview 13th of October, 2022 – Radisson Blu Hotel Zurich Airport

	TRACK 1	TRACK 2	TRACK 3	TRACK 4
TIME CEST	AI/ML AND STRUCTURAL APPROACHES	INNOVATIVE & EMERGING MODALITIES	CHEMICAL BIOLOGY / UNDRUGGABLES & HIT TO LEAD OPTIMIZATION	INTEGRATED DRUG DISCOVERY
08:00 - 08:30	REGISTRATION AND WELCOME			
08:30 - 09:00	OPENING KEYNOTE PRESENTATION Untapped Market: Novel Therapeutics For High Unmet Medical Need			
09:00 - 10:00	Confronting The Challenge Of Solubility Of Lead Compounds Through Structural Modifications In The Early Drug Discovery Phase	Small Drugs, Big Impact: The Extraordinary Role Of DNA and RNA In Drug Development And Research	Discovering The Future Of AI/ML In Preclinical Discovery And How To Determine ADMET Properties	Assessing Innovative Approaches To Further Improve The Small-Molecules Drug To The Targeted Cancer Treatment
10:00 - 10:20	NETWORKING / 1-1 MEETINGS			
10:20 - 10:40	NETWORKING / 1-1 MEETINGS			
10:40 - 11:00	NETWORKING / 1-1 MEETINGS			
11:00 - 12:00 SOLUTION	Exploring the Best Strategies to Leverage AI Technologies in the Pharma and Biotech Industry AINNOCENCE Ainnocence	Small Drugs, Big Impact: The Extraordinary Role Of DNA and RNA In Drug Development And Research FOR SPONSOR	Expanding The World Of E3 Ubiquitin Ligases: Adapting Innovative Approaches For Better Protein Degradation FOR SPONSOR	Novel Drug Modality Update: Current Advances In Antibody-Drug Conjugates As Therapeutic Option FOR SPONSOR
12:00 - 13:00	NETWORKING LUNCH			
13:00 - 13:30	KEYNOTE PRESENTATION Creating impactful leadership using biotech and innovation			
13:30 - 13:50	NETWORKING / 1-1 MEETINGS			
13:50 - 14:10	NETWORKING / 1-1 MEETINGS			
14:10 - 14:30	NETWORKING / 1-1 MEETINGS			
14:30 - 15:30	An Exploration For Fragment-Based Drug Discovery: Discussing How To Effectively Navigate Fragment-Based Drug Discovery Method	New Drug Discovery Paradigm: Exploring Advances In Drug Discovery Using Novel Target-Based Approaches To Accelerate Target Discovery	Going beyond PROTACs: tackling undruggable targets using induced proximity based therapeutics (e.g. DUBTACs, LYTACs, RIBOTACs)	Assessing Structural Kinome and Its Implications for Kinase Drug Discovery
15:30 - 16:30	DRINKS & CANAPES RECEPTION			

PROVENTA INTERNATIONAL

IN PARTNERSHIP WITH:

HAMILTON
THE MEASURE OF EXCELLENCE®

STRATEGY DINNER

"Smart PAT" (PAT = Process Analytical Technology).

Biopharmaceutical manufacturing is a notoriously complicated process. A major challenge in this process is the product itself - particularly for biologics manufacturing. Proteins are highly complex molecules with many closely related, but functionally different, variants., These realities can make analysis and control difficult. Traditional quality control methods are over-reliant on lab work for process sampling and analytics: often, labs, their location, capacity and the costs associated with them act as bottlenecks. Improving quality controlprocesses requires a true disruption of the traditional in-lab work with an advancement to smart quality control. Smart quality control shifts quality and performance monitoring to the shop floor to enable in-line monitoring, automated process control, and real-time release. This is achieved through harnessing cutting-edge technologies to realize increased cost-efficiencies throughout the supply chain.

Attendees will be able to address these issues and the innovations solving them, such as:

- New real-time measurement technologies that overcome the challenges of durability, specificity, and speed to measure PAT Critical Process Parameters and Key Performance Indicators during the process.
- Progressing digitalization to enable innovative process analytics (soft sensors), advanced process control (e.g. digital twin simulation), preventative maintenance, and asset management.

AGENDA

17:15–18:00	REGISTRATION, NETWORKING & COCKTAILS
18:30-19:00	WELCOME AND INTRODUCTION
19:00-20:00	ROUNDTABLE DISCUSSION **Title: Smart, connected and controlled: The new bioprocesses.** **Speaker:** Martin Mayer, Business Development Smart Engineering Services & Digitalization at ZETA GmbH • Digitalization and Smart Sensors for Bioprocesses • Use of measurement data for process optimization and closed loop control in operations • FDA take on ML / Advanced Process Control • Learnings and outlook
20:00-20:45	DINNER
20:45-21:45	ROUNDTABLE DISCUSSION **Title: Of plasmids, proteins and viral vectors: (soft) sensors for the production of novel biopharmaceutical modalities.** **Speaker:** Prof. Dr. Thomas Villiger, Prof. of Bioprocess Technology at University of Applied Sciences Northwestern Switzerland (FHNW) • Advantage of using simple and robust mechanisms over complicated mathematical models • Applying soft sensor triggered fed-batch platform for plasmid and protein production • Utilizing product quality control by biocapacity measurements in continuous cell culture processes • Discussing the capabilities and limitations of Raman spectroscopy
21:45-22:00	CLOSING REMARKS AND COFFEE

11TH OCTOBER 2022
TUESDAY

Radisson BLU HOTEL, ZURICH AIRPORT

Zurich Airport,
8058, Switzerland

Key Opinion Leaders

Prof. Dr. Thomas Villiger
Prof. of Bioprocess Technology
University of Applied Sciences Northwestern Switzerland (FHNW)

Thomas Villiger received his Msc and PhD in Chemical and Bioengineering from ETH Zurich. He gained more than a decade of industrial experience in bioprocess development and manufacturing at Merck, Novartis and Biogen. Since 2019, he is head of the Bioprocess Technology Laboratory at the University of Applied Sciences Northwestern Switzerland (FHNW) in Muttenz, Basel. His research focuses on upstream and downstream processes for antibodies, viral vectors, and other complex biologics, with particular emphasis on the application of process analytical technologies and data science tools to develop new manufacturing strategies, intensify processes, and control product quality.

Martin Mayer
Business Dev Smart Engineering Services & Digitalization
ZETA GmbH

Martin Mayer studied industrial engineering and business at the Technical University Graz. During his career a wide variety of senior roles from business development, research and development responsibility to general management challenged his skills within more than 15 years of interesting international work.
Within that time he was responsible for a number of projects in chemical industry, Pulp and Paper as well in biotech/ biopharma industry mainly in the field of digitization, data management, data analytics and model based optimization (DoE). Within the last years the growing awareness for digitalization topics within the pharma industry in combination with the harmonization activities (ICH Q8-Q12) have formed excellent boundary conditions for the establishment of new products and services, not only in the manufacturing sector, but especially in the field of R&D (Data Management in R&D, advanced control strategies for conti processes,...). Within ZETA he is responsible for business development in the field of Smart Engineering Services and Digitalization. Martin Mayer is member of the Steering Commitee for the Plug&Produce activities within the ISPE Pharma 4.0 program.

Contact Details:
KATH DE VELA
kv@proventainternational.com
+1 (617) 4534896 ext 325
www.proventainternational.com

STRATEGY DINNER

Seamless global strategy for NCE development and API supply chain by optimizing technology, providing collective expertise, and reducing the delivery time and cost – an unmet need

The "heart of drug development" is to employ innovative technologies and collaborations across the globe, to assemble a powerful Drug Development Engine to accelerate candidates from drug discovery, PRD, scale-up through commercialization. The best way to increase the valuation of drug discovery and development pipeline and company's portfolio is to accelerate their milestones, reduce costs while maintaining quality. Today's CDMO industry is lacking a unique collective expertise in one place, utilizing ground-breaking technologies for the synthesis of architecturally complex molecules that can intercept any molecule, at any stage of development. Ultimately the know-how of phase appropriate execution, 'shaving' months off the development cycle time and a "one stop shop" of delivery of entire CMC management is an unmet need.

OCT 12
WEDNESDAY

Radisson Blu

Radisson Blu Hotel Zurich Airport

AGENDA	
17:00 - 18:00	Registration, Networking & Cocktails
18:00 - 18:15	Welcome & Introductions Swapan Bhattacharya, *Managing Director*, TCG Lifesciences Pvt. Ltd. Sanjoy Kumar Mahanty, Ph.D, *Vice President & Head of Business Development-NA*, TCG Lifesciences Pvt. Ltd.
18:15 - 19:15	Roundtable Discussion on: Big Pharma training with Biotech mentality to "Accelerate Molecules to Medicines" • Solving complicated CMC problems for NCEs adopting "First Time Right" techniques for First in Human studies • Reducing timelines by utilizing optimized "Drug Development Engine" • Leveraging innovative technologies embedded in Process Research and Development for API • Utilization of dynamic cost structure model • Tapping global resource pool • US management oversight operation • 24 hr/day for solving problems and deliveries • Smooth tech transfer for API in a global setting • Implementing collective expertise of globally based scientists, scientific project managers and engagement with client-based approach • Maintaining transparency and IP protection Joseph D. Armstrong, III, Ph.D, *COO*, TCG GreenChem, Inc. (NJ & VA, USA)
19:15 - 20:30	Dinner
20:30 - 21:30	Roundtable Discussion: Continue the topic Big-Pharma training with Biotech mentality to "Accelerate Molecules to Medicines" Subho Roy, Ph.D, *Vice President - Business Head*, Clinivent Research Pvt. Ltd, A 100% subsidiary of TCG Lifesciences
21:30 - 22:00	Closing Remarks, Coffee & Cognacs Vishal Rajput, Ph.D, *Vice President, Business Development*, TCG Lifesciences Pvt. Ltd. Dr. Gopal Sirasani, *Associate Vice President, CDMO Business Development & Technical Operations*, TCG GreenChem

KEY OPINION LEADERS

Swapan Bhattacharya - *Managing Director*, TCG Lifesciences Pvt. Ltd.

Swapan Bhattacharya is the Managing Director of TCG Lifesciences (TCGLS) and is responsible for the executive leadership and overall management of the company. He co-founded TCGLS in 2001 and has taken the Company to a global leadership position in the research services space. He is also a key member of the Governing Council of the TCG Centers for Education and Research in Science and Technology, a not-for-profit institute in the process of spawning multiple centers of excellence in the frontier fields of translational neuroscience and oncology, AI and quantum computing. He has been associated with the TCG Group since 1995 and has spearheaded the group's investments in India and its entry into life sciences domains from 1998. His professional career has spanned across the globe for about 40 years. Prior to joining the Group, he has held positions with PaineWebber Inc. as Senior Vice President and as Consultant to the US Nuclear Regulatory Commission. Over the years, he has held leadership committee positions in US India Business Council, FICCI, AMCHAM and Assocham; several board positions; and received excellence awards. He holds a bachelor's degree in engineering from the Indian Institute of Technology, Kharagpur, a master's degree from the Virginia Polytechnic Institute and State University, U.S.A and an MBA from Kellogg School of Management, Northwestern University, U.S.A. He received the Lester Cunningham Award for academic excellence at Northwestern.

Sanjoy Kumar Mahanty, Ph.D - *Vice President & Head of Business Development-NA*, TCG Lifesciences Pvt. Ltd.

Dr. Sanjoy Kumar Mahanty is part of the core business development, account management, marketing & sales team in the USA. Dr. Mahanty has twenty-five years of expertise in scientific research, and extensive leadership experience in drug discovery & development process. Dr. Mahanty has been associated with TCG Lifesciences for over eight years. He has been highly successful in penetrating CRO/CDMO markets globally, and proven track-record in establishing the new business, and maintaining existing clients. He holds a bachelor's degree from Utkal University, and a master's of sciences (MSc) & PhD degree in Biochemistry from Jawaharlal Nehru University, New Delhi, India. Dr. Mahanty completed his Post-Doctoral Research Experience from Harvard Medical School, Boston, and University of North Carolina, Chapel Hill, USA. He has eighteen co-authored peer reviewed publications including one in the highly reputed journal CELL, one book chapter, and ten shared patents to his credit.

Joseph D. Armstrong, III, Ph.D - *COO*, TCG GreenChem, Inc. (NJ & VA, USA)

Dr. Armstrong is a high energy scientific and executive leader with 28 years of experience at Merck & Co., Inc. in Process Research, Formulation Development and Project Management with deep knowledge and experience of all drug discovery and development processes to support IND to NDA filings. As the Merck Preclinical Integration Lead (Process R&D, Formulation R&D, DMPK, Safety Assessment, and Clinical Supplies) for the merger with Schering Plough, created a multidisciplinary organization that leveraged development knowledge to accelerate identification of Preclinical Candidates and their rapid entry into the clinic and beyond. He led the cross-functional team that filed the drug Januvia™ for the treatment of type II diabetes in less than 4 years by executing new green and sustainable technologies and strategies. He led the Process R&D Team that discovered the novel asymmetric hydrogenation process for the preparation of Sitagliptin, the active ingredient in Januvia™ . This team received the Thomas Edison award, the EU IChemE Aztra-Zeneca Award for Green Chemistry and Engineering and the US Presidential Green Chemistry Challenge Award.

Subho Roy, Ph.D - *Vice President - Business Head, Clinivent Research Pvt. Ltd*, A 100% subsidiary of TCG Lifesciences

Dr. Subho Roy Joined the group in 2002 and has been one of the key leadership members responsible for the growth of the company. He holds a Ph.D degree from Indian Institute of Chemical Technology, working with Dr. A.V.Rama Rao, on synthesis of natural products of biological importance and subsequently spent few years at the University of Kansas, Lawrence, USA, working with Dr. Gunda Georg for his post-doctoral studies. He has more than 20 years of Industrial experience of progressing small molecules coming out of R&D through various phases of development and taking them all the way to commercialization. He is a specialist in new process development, optimization and various other aspects of CMC. Dr. Roy has several publications to his credit and holds several European and US patents. He has played a key role in conceptualizing and designing of the manufacturing facility, "Clinivent Research Pvt. Ltd.", a 100% subsidiary of TCG Lifesciences, which has successfully completed US FDA inspection.

Vishal Rajput, Ph.D - *Vice President, Business Development*, TCG Lifesciences Pvt. Ltd.

Dr. Vishal Rajput holds Masters in Chemistry from IIT Roorkee, he is a Ph.D in Medicinal Chemistry from CDRI Lucknow, and a Post Doctorate from Lund University, Sweden and University of Alberta, Canada. He also holds PG diploma in patent Law from NALSAR Law University, Hyderabad. He is a seasoned techno-commercial professional with experience in Pharma/Life science Industries spans across Business Development (CDMO), API-Sales, Project and Portfolio Management and in R&D from top-tier pharma and biotech companies like Syngene Intl Ltd. Merck and Sigma-Aldrich etc. His last assignment was with Shilpa Medicare Ltd. as Head of Global CDMO Business- Drug Substance and Drug Product. He also has cross value chain expertise and Business Development experience covering discovery, development and manufacturing services for small and large molecules (ADC, NCE, Carbohydrates, Polymer and peptide) API for global Innovator and Generic companies.

Dr. Gopal Sirasani - *Associate Vice President, CDMO Business Development & Technical Operations*, TCG GreenChem

Dr. Gopal Sirasani is the Associate Vice President, CDMO Business Development & Technical Operations of TCG GreenChem. He is responsible for key account management, marketing, and sales operations. He has been highly successful in establishing new business collaborations between biotech companies and TCG GreenChem/TCG Lifesciences. Dr. Sirasani is heavily involved in tracking the customer projects for CMC development, in terms of route scouting, process development, scale-up operations and cGMP/non-GMP campaigns to deliver for preclinical and clinical needs of the clients. Dr. Sirasani received his bachelor's in Chemical Technology, Masters in Drugs and Pharmaceuticals, Ph.D. in Synthetic Organic Chemistry at Temple University, Philadelphia, and Post-Doctoral training at Harvard University. In total, he has 18 years of academic and industrial experience.

At TCG, we address these needs with a proven strategy utilizing the following inherent strengths:

- Top tier and experienced people from big-Pharma
- Large PRD group working across the globe
- Trust-based client relations and depth of engagement spanning two decades
- High end technology platforms and science, like continuous chemistry, catalysis
- Operational synergies amongst group companies
- World class facilities and infrastructure

We deliver integrated end-to-end solutions to the global life sciences' industries.

PROVENTA INTERNATIONAL

IN PARTNERSHIP WITH:

TCG Lifesciences | CHEMBIOTEK

TCG GreenChem

Why Book Your V.I.P Seat Now?

- Be amongst 10-15 Industry thought leaders from a mix of large Pharmaceutical Institutions ensuring you are given ample opportunity to raise questions and contribute from a strategic perspective.
- Wine, dine and network with industry leaders who face common challenges in 60-minute roundtable discussions that enable you to share ideas and lessons learned.
- Facilitated by expert moderators, these sessions provide a valuable dialogue with peers on current challenges and topical issues.
- No media, marketing or press, just pure and honest discussion to help solve your key strategic challenges for the next 3-9 months.

Contact Details:
GEN AMORILLO
ga@proventainternational.com
+1 (617) 4315492 ext 327
www.proventainternational.com

Event Day

OPENING KEYNOTE PRESENTATION

8:30 – 9:00 CEST

Untapped Market: Novel Therapeutics For High Unmet Medical Need

Asif Ahmed
Executive Chairman and CEO
Mirzyme

KEYNOTE PRESENTATION

13:00 – 13:30 CEST

Creating impactful leadership using biotech and innovation

Asif Ahmed
Executive Chairman and CEO
Mirzyme

TRACK 1:
AI/ML AND STRUCTURAL APPROACHES

Large quantities of biological and medical data brought by increased digitalization in the industry go hand in hand with next-level machine cognition to aid efforts involving drug discovery & development, synthesis, drug repurposing, modeling & simulation, predicting protein attachment, clinical trials, and beyond. Hundreds of novel targets and potential for future drug development have been identified through genomic, proteomic, and structural research. This track explores verifiable use of advanced technologies to analyze data, predict structure and activity, aid in hit finding, focuses on modifying and optimizing the structure of a drug candidate through the use of innovative tools and technologies and more.

9:00 – 10:00 CEST

ROUNDTABLE 1:
Confronting The Challenge Of Solubility Of Lead Compounds Through Structural Modifications In The Early Drug Discovery Phase

- Identifying possible obstacles in lead candidate success to minimize failure rate
- Finding innovative solutions for improving the solubility of a lead compound without losing the potency
- Examining approaches towards the design and modification of structure to increase the solubility and pharmacokinetic/physicochemical parameters of the lead compound

Daniel Gironés
Senior Vice President Drug Discovery
Protinhi Therapeutics

11:00 – 12:00 CEST

SOLUTION FOCUS ROUNDTABLE 2:
Exploring the Best Strategies to Leverage AI Technologies in the Pharma and Biotech Industry

- AI experts: What are the remaining obstacles to using AI technology (Internally/Externally) in drug discovery?
- Toward the chemists: Given that the application of AI technologies has expanded the potential of the drug discovery chemist in areas such as target selection, hit finding and optimization, effective binding affinity prediction, and screening up to billions of compounds reliably, are there any remaining bottlenecks in your current workflows?
- Towards the biologist/bioinformatician: In leveraging AI in target identification and DMPK/ADMET, which applications have you found to be absolutely necessary, and which ones require more research in order to contribute to breakthroughs?
- Bioinformatics/chemistry/biology/AI: Another approach where AI has shown potential has been the use of multi-omics across a number of fields to characterize disease-causing pathways and reveal clinically significant targets. Could there perhaps be a bigger role for AI in the field? Some postulate that neural networks may make omics integration more effective, or even make the integration of omics with non-omics data feasible
- A growing belief is that by leveraging advanced computational design technologies, traditional chemists will soon be out of a job. Is this the case, or are we on the verge of the age of the ultimate medicinal/computational chemist? Should these roles be kept distinct, and if so, to what extent?
- AI is a rising technology: What do you think of the regulatory, liability, and ethical implications that would rise if AI were to be deployed in decision-making roles, and how they should be tackled?
- Given the excitement that surrounds protein structure predictive technologies such as AlphaFold, the question of whether there is truly a need for structure prediction to design effective molecules remains. What is the true significance of the technology, and will it be absolutely essential as researchers seek to tackle new targets?
- What business models would best serve your R&D needs, SAAS, project-based service like traditional CRO, royalty shared pipeline co-development, pre-IND license out, or others

Dr. Lurong Pan
Founder and CEO
Ainnocence

AINNOCENCE

Ainnocence

14:30 – 15:30 CEST

ROUNDTABLE 3:
An Exploration For Fragment-Based Drug Discovery: Discussing How To Effectively Navigate Fragment-Based Drug Discovery Method

- Fragment-based drug discovery: What does the future hold?
- Maximizing the success of fragment-based drug discovery in the fragment-to-hit-to-lead stages
- Managing pros and cons of both Fragment-based and HTS: How can we develop and evaluate benefits while addressing drawbacks at the interface?

Edgar Jacoby
Senior Principal Scientist Computational Chemistry
The Janssen Pharmaceutical Companies of Johnson & Johnson

Event Day

TRACK 2:
INNOVATIVE & EMERGING MODALITIES

Despite the reinvigorated R&D engine and reinstated productivity, challenges and opportunities remain unanswered, such as optimized druggability, pharmacokinetics and safety, enhanced bioavailability, delivery, and more. This track aims to tackle these current barriers, formulate an outlook strategy and explore the emerging modality space.

11:00 – 12:00 CEST

ROUNDTABLE 2:
Small Drugs, Big Impact: The Extraordinary Role Of DNA and RNA In Drug Development And Research

- Therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are some of the most important biopharmaceuticals that are in commercial space as future medicines. Addressing the challenges of the intracellular stability of miRNA and siRNA to further enhance its therapeutic potential
- Unique target discovery tools: What are the challenges and innovative solutions in Drug Development?
- Short synthetic DNA/RNA molecules, Antisense Oligonuecletides' Future Prospects: Could it be the solution for incurable diseases?

Asif Ahmed
Executive Chairman and CEO
Mirzyme

14:30 – 15:30 CEST

ROUNDTABLE 3:
New Drug Discovery Paradigm: Exploring Advances In Drug Discovery Using Novel Target-Based Approaches To Accelerate Target Discovery

- Understanding the disease's mechanism of action is the first step in target identification and validation, followed by hit identification, hit-to-lead, and lead optimization: How ready and advanced are we?
- What was once old has become new again: The comeback of Phenotypic Drug Discovery (PDD) for Novel Target-Based Approaches
- Discussing the key challenges of PDD: Insufficient tools for analyzing and prioritizing hits resulting in poor leads, as well as lead progression via unfavorable treatments that fail at more expensive phases of discovery

Daniel Girones
Senior Vice President Drug Discovery
Protinhi Therapeutics

TRACK 3:
CHEMICAL BIOLOGY / UNDRUGGABLES & HIT TO LEAD OPTIMIZATION

This track tackles pressing topics that interrogate and discern biological function by exploring small molecule modulation, undruggable targets, Target Protein Degradation, high throughput biology techniques, and more, to better understand probe development and uncover novel and therapeutically relevant targets.

9:00 – 10:00 CEST

ROUNDTABLE 1:
Discovering The Future Of AI/ML In Preclinical Discovery And How To Determine ADMET Properties

- Capitalizing on the power of advanced technologies such as AI/ML to determine the ADMET properties of a compound
- Discussing how to resolve insufficient data in AI/ML algorithms of previously screened data compounds
- Exploring possible solutions in the pressing industry challenge in achieving a more accurate ADMET profiling

Henrik Keränen
Research Scientist and Head of Computational Chemistry Section
Lundbeck

14:30 – 15:30 CEST

ROUNDTABLE 3:
Going beyond PROTACs: tackling undruggable targets using induced proximity based therapeutics (e.g. DUBTACs, LYTACs, RIBOTACs)

- Which induced proximity based modalities are most promising and worth investing?
- Which tools/methods do we need to establish in the future to more efficiently discover and optimize induced proximity-based modalities?
- With the molecules becoming bigger, how can we tackle challenging physicochemical properties and delivery more efficiently?
- What skill set do we need to acquire (and hire) to ensure future success with induced proximity-based modalities?

Stefan Schiesser
Associate Principal Scientist
AstraZeneca

Intimate format events where senior leadership discuss the biggest challenges facing the industry.

Event Day

TRACK 4:
INTEGRATED DRUG DISCOVERY

Overcoming the high attrition rates of the development process, particularly in drug discovery and optimization remains a significant hurdle and a top priority in the pharma and biotech sector. The track explores effective strategies to break down discipline segmentation and foster an improved integrated approach to drug discovery.

09:00 – 10:00 CEST

ROUNDTABLE 1:
Assessing Innovative Approaches To Further Improve The Small-Molecules Drug To The Targeted Cancer Treatment

- Discuss approaches to further understand the value of small molecules in cancer treatment
- Analyzing the effectiveness of small molecule drugs towards different cancer inhibitors
- Evaluating the strategies in improving the pharmacokinetics of small molecule drugs in vivo/vitro
- Overcoming limitations in target delivery, drug resistance, and long-term safety of Small-molecules drugs

Philippe Pinton
Vice President and Global Head Translational Medicine & Clinical Pharmacology
Ferring Pharmaceutical

14:30 – 15:30 CEST

ROUNDTABLE 3:
Assessing Structural Kinome and Its Implications for Kinase Drug Discovery

- The structural understanding and consequences for the design of new inhibitors
  - Active vs. inactive kinase
  - Type 1 inhibitors
  - Allosteric binders and novel pockets
  - Covalent kinase drugs
- New modalities in kinase drug discovery, PROTACs and molecular glues
- Indications beyond Oncology
- The future of kinases as drug targets

Guido Koch
Chief Executive Officer,
Amphilix

MEETING CONCLUDE

Please contact:
info@proventainternational.com
to register your interest

OR
SCAN HERE
TO REGISTER



Venue

Radisson Blu Hotel, Zurich Airport

Welcome to the Radisson Blu, the only hotel with direct access to the terminal at Zürich Airport. The hotel is just a short walk from the airport train station, and from there it's only a 10-minute train ride to downtown Zürich.

HOTEL DETAILS → MAP & DIRECTIONS →

OUR FACE-TO-FACE MEETING IN OCTOBER & NOVEMBER 2022

Strategy Meeting Zurich and Boston

Zurich - Europe

OCT 10 MON — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 11 TUE — BIOMANUFACTURING
Biomanufacturing Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 12 WED — REGULATORYAFFAIRS
Regulatory Affairs Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 13 THUR — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 10 MON — CLINICALTRIALSUPPLYCHAIN
Clinical Trial Supply Chain Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 11 TUE — CELLANDGENETHERAPY
Cell & Gene Therapy Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 12 WED — CHEMISTRYMANUFACTURINGCONTROL
CMC Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

Boston/Cambridge MA - US East Coast

NOV 08 TUE — ONCOLOGY
Oncology Strategy Meeting 2022
Le Meridien Cambridge

NOV 10 THUR — REGULATORYAFFAIRS
Regulatory Affairs Strategy Meeting 2022
Le Meridien Cambridge

NOV 15 TUE — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Le Meridien Cambridge

NOV 09 WED — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Le Meridien Cambridge

NOV 14 MON — DRUG DISCOVERY BIOLOGY
Drug Discovery Biology Strategy Meeting 2022
Le Meridien Cambridge

*Reinvigorating Productivity in **Pharma & Biotech R&D** Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms*

Register Now! →
info@proventainternational.com